Company: HURA
Filing Date: 2025-11-03
Form Type: S-3
Source: 0001193125-25-262843
Chunk: 54

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-11-03
Form: S-3
Chunk 54
---
21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements include, without limitation, statements regarding the financial position, business strategy, and plans and objectives of management for future operations, and any statements that refer to characterizations of future events or circumstances, including any underlying assumptions. These statements constitute projections, forecasts, and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. These forward-looking statements generally are identified by the words “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential”, or “continue” or the negative of these terms or other similar expressions. Such forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, those described below:

| • |     | our ability to raise funds for general corporate purposes and operations, including our research activities and 
 clinical studies;                                                                                               |

| • |     | our ability to realize the anticipated benefits of the merger (the “Kineta Merger”) with Kineta, Inc. 
 (“Kineta”);                                                                                           |

| • |     | the effects of the Kineta Merger on our business relationships, operating results and business generally; |

| • |     | expectations regarding the strategies, prospects, plans, expectations and objectives of our management for future 
 operations of our company following the closing of the Kineta Merger;                                             |

| • |     | unexpected costs, charges or expenses resulting from the Kineta Merger; |

| • |     | the cost, timing, scope and results of our clinical studies; |

| • |     | existing regulations and regulatory developments in the United States and other jurisdictions; |

| • |     | our ability to attract and retain key scientific, medical, commercial and management personnel; |

| • |     | our ability to obtain and maintain required regulatory approvals for our products; |

| • |     | our expectations regarding the use of our existing cash; |

| • |     | the therapeutic potential of IFx-Hu2.0,            
 IFx-Hu3.0, TBS-2025